---
title: "HCC"
date: "2023-12-05 09:57:35"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ªï¼š[[snippets]]

# HCC

- [[epidemiology-of-hepatocellular_carcinoma.md|Epidemiology-of-hepatocellular carcinoma]]
- [[systemic_therapies-of-hepatocellular_carcinoma.md|Systemic therapies-of-hepatocellular carcinoma]]
    - [[subsequent_therapies-of-hepatocellular_carcinoma.md|Subsequent therapies-of-hepatocellular carcinoma]]

### Hepatocellular carcinoma s/p ?

- Initial presentation:
- EGD on 2017/00/00:
- CT on 2017/00/00:
- Follow up parameter: CXR, Dynamic CT, and AFP
- Treatment plan: sorafenib +- TACE if feasible: sorafenib 200mg BID 2017/00/00~
- 2017/00/00: Explain the purpose of palliative treatment is to control disease and prolong life and maintain quality of life but not cure. Discuss treatment choice of sorafenib but very poor response rate.
  @ Plan to start palliatve targeted therapy with dose of 200mg BID, explain AEs
  @ Arrange EGD first before started targeted therapy
  @ Pharmacist education before targeted therapy
  \*possible side effect of sorafenib was told, such as hypertension, hand-food syndrome, skin rash, GI upset, diarrhea, and bleeding

### HBV/HCV/Alcoholic liver cirrhosis, child A, complicated with minimal ascites, splenomegaly and portal hypertension

### Siblings
